« Previous | Next » | All Messages |  XKEM Message Board Home | recommend post |  Ignore Poster

XKEM News Xechem Update From The Recent 10th Annual NYSSA Biotech Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM) announced today that Xechem was well received and applauded for Dr. Pandey’s work in developing and bringing to market the best treatment in 30 years to relieve the suffering of patients from Sickle Cell Disease (SCD) in Nigeria and throughout the world at the 10^th Annual New York Society of Security Analysts Biotech Conference, December 12^th/13^th, 2006. Some of the highlights given by Dr. Pandey at the conference were: revenues in the first year of full production are estimated to be in the $30 million range, with a 3 to 5 year outlook of $75 - $100 million in Nigeria alone, assuming current pricing and further premised upon Xechem procuring necessary financing, receiving continued regulatory approval from Nigeria and completing construction of the Nigeria manufacturing plant; Worldwide market for Sickle Cell treatment is believed to be 16-18 million patients, with 10 million in Africa; the Nigerian government has raised the priority of Sickle Cell Disease to number two following AIDS at number one. They have also stated that the Nigerian Government will help pay for the treatment of those individuals that cannot pay for NICOSAN™. Dr. Pandey’s presentation can be accessed through the Xechem Web Site at www.xechem.com.

Dr. Pandey introduced the new Managing Director for Xechem Pharmaceutical Nigeria, Mr. Iretiolu Oniyide, who comes to the Company with a distinguished career in the banking and pharmaceutical fields for over 30 years.

Xechem is also preparing an IND application to the FDA for US clinical trials to begin on HEMOXIN™ which is the name of NICOSAN™ for the US and Europe. Five US hospitals have agreed to take part in the clinical trials. UMDNJ, Children’s Hospital of Philadelphia, SUNY-Brooklyn, Thomas Jefferson and Howard University hospitals. The opening of new Xechem offices in the UK will enable future clinical trials in Europe.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetics, antimalarials, antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (named HEMOXIN™ for the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent limited Nigerian regulatory approval of NICOSAN™, Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.